Artificial intelligence improves diagnostic accuracy and treatment planning in prostate cancer management
Artificial Intelligence Shows Potential for Prostate Cancer Diagnosis and Treatment
This narrative review examines the role of artificial intelligence in diagnosing and treating prostate cancer. The authors conclude that AI-…
New research explores how artificial intelligence can improve the accuracy of prostate cancer diagnosis and help create more personalized tr…
PSMA-targeted radioligand therapies including 177Lu-PSMA-617 improve progression-free survival and overall survival in mCRPC
Radioligand Therapy Shows Promise for Advanced Prostate Cancer Patients
This narrative review examines the clinical role of PSMA-targeted radioligand therapies, specifically 177Lu-PSMA-617, 225Ac-PSMA, and 223Ra …
New radioligand therapies like 177Lu-PSMA-617 show improved survival rates for patients with advanced and metastatic prostate cancer.
Late grade 2 or higher gastrointestinal toxicity is inversely associated with biochemical recurrence in prostate cancer
Gastrointestinal Toxicity Linked to Lower Prostate Cancer Recurrence Rates
This individual patient data meta-analysis of 6761 patients receiving conventional or moderately hypofractionated radiation therapy found th…
A large study found a link between certain side effects from radiation and lower rates of prostate cancer recurrence in over 6,700 patients.
Post-diagnosis physical activity of 7.5 MET-hr/week associated with lower all-cause mortality in prostate cancer
Higher physical activity linked to lower death rates in prostate cancer
This meta-analysis of 10 studies involving over 50,144 men with prostate cancer found that higher levels of post-diagnosis physical activity…
Men with prostate cancer who stay active after diagnosis may have a lower risk of death from all causes.
MRI-based artificial intelligence models show promise in predicting biochemical recurrence in prostate cancer
AI models help predict prostate cancer recurrence from MRI scans
Researchers evaluated the diagnostic performance of MRI-based artificial intelligence models for predicting biochemical recurrence in patien…
New data shows that artificial intelligence can accurately predict if prostate cancer will return after treatment by analyzing MRI images.
Biparametric MRI noninferior to multiparametric MRI for detecting clinically significant prostate cancer
Biparametric MRI shows similar accuracy to multiparametric MRI for prostate cancer
A meta-analysis of 9403 men with suspected prostate cancer found that biparametric MRI (bpMRI) is noninferior to multiparametric MRI (mpMRI)…
A new analysis suggests that a simplified MRI technique may be just as accurate as standard methods for detecting significant prostate cance…
Radiomics models predict biochemical recurrence after prostatectomy with 0.82 sensitivity
New computer models help predict prostate cancer recurrence after surgery
This meta-analysis of 3634 patients found that radiomics-based models predict biochemical recurrence after radical prostatectomy with a pool…
Advanced imaging analysis helps doctors better predict if prostate cancer will return after surgery, allowing for more personalized care.
PSMA-targeted radioguided surgery shows high diagnostic accuracy in prostate cancer meta-analysis
PSMA guided surgery shows better accuracy for prostate cancer
This meta-analysis of 28 studies evaluates PSMA-targeted radioguided surgery (PSMA-RGS) for prostate cancer. PSMA-RGS demonstrated high sens…
New data shows that PSMA targeted radioguided surgery provides higher accuracy than standard imaging to find and locate prostate cancer.
PSMA-targeting radiotracers exhibit varying liver background uptake levels impacting patient selection for targeted therapy
PET scan tracer choice may affect prostate cancer treatment eligibility
This systematic review and meta-analysis of 17 studies involving 1497 patients evaluated four PSMA-targeting PET radiotracers. The analysis …
Which PET tracer you get for prostate cancer could change whether you qualify for targeted therapy. A new analysis shows big differences in …
Meta Analysis Evaluates Hypokalemia Risks Associated with Androgen Receptor Axis Targeted Therapies
New Analysis Shows Risk of Low Potassium with Prostate Cancer Drugs
A meta-analysis of 9,298 patients reveals that abiraterone and combination therapies significantly increase hypokalemia risk in advanced pro…
Certain prostate cancer treatments, especially abiraterone and combination therapies, are linked to a significantly higher risk of low potas…
Higher serum vitamin D levels linked to small increase in prostate cancer risk
Higher Vitamin D Levels Linked to Increased Prostate Cancer Risk
An umbrella review of observational studies found a small but statistically significant association between higher serum vitamin D levels an…
A review of observational data suggests a small link between higher vitamin D levels and increased risk of prostate cancer.
Catheterisation Linked to Small PSA Rise in Men
Urinary Catheters May Cause Small Increases in Prostate PSA Levels
A meta-analysis of 9 studies found that indwelling urethral catheterisation causes a small but statistically significant increase in serum P…
Short-term urinary catheters can cause small increases in prostate PSA levels, but these changes may not affect clinical decisions for short…
Questions about Prostate Cancer
Can dose intensification improve outcomes for intermediate- or high-risk prostate cancer?
Yes, early evidence suggests dose intensification to visible tumors may improve outcomes for intermediate- or high-risk prostate cancer, but ongoing trials will clarify safety and efficacy.
Full answer →Is there more research on macrophage polarization for prostate cancer since 2015?
Yes, research on macrophage polarization in prostate cancer has grown significantly since 2015, with studies exploring its role in tumor progression and therapy resistance.
Full answer →Can enzalutamide plus ADT improve survival for metastatic hormone-sensitive prostate cancer?
Yes, enzalutamide plus ADT significantly improves survival in metastatic hormone-sensitive prostate cancer, with a 34% reduction in risk of death and a 5-year survival rate of 66% versus 53% with ADT alone.
Full answer →All Prostate Cancer Articles
- Artificial intelligence improves diagnostic accuracy and treatment planning in prostate cancer management
- PSMA-targeted radioligand therapies including 177Lu-PSMA-617 improve progression-free survival and overall survival in mCRPC
- Late grade 2 or higher gastrointestinal toxicity is inversely associated with biochemical recurrence in prostate cancer
- Post-diagnosis physical activity of 7.5 MET-hr/week associated with lower all-cause mortality in prostate cancer
- MRI-based artificial intelligence models show promise in predicting biochemical recurrence in prostate cancer
- Biparametric MRI noninferior to multiparametric MRI for detecting clinically significant prostate cancer
- PSMA-targeted radioguided surgery shows high diagnostic accuracy in prostate cancer meta-analysis
- Radiomics models predict biochemical recurrence after prostatectomy with 0.82 sensitivity
- PSMA-targeting radiotracers exhibit varying liver background uptake levels impacting patient selection for targeted therapy
- Meta Analysis Evaluates Hypokalemia Risks Associated with Androgen Receptor Axis Targeted Therapies
- Higher serum vitamin D levels linked to small increase in prostate cancer risk
- Catheterisation Linked to Small PSA Rise in Men
- Meta-analysis Evaluating Occupational Hexavalent Chromium Exposure and Specific Malignancy Risks
- Prostatic incidental uptake on FDG PET/CT has a 1.7% prevalence with 21.3% malignancy risk
- Diffusion tensor imaging metrics may improve diagnostic specificity for pelvic floor anatomical conditions
- Solid organ transplant recipients face higher cancer-related mortality with SMR 2.21 across multiple organs
- Infliximab may offer clinical improvement and wound reduction in non-Crohn's disease related fistulas
- Arecoline may upregulate androgen receptor in prostate cancer cells, integrative analysis suggests
- Aglatimagene plus valacyclovir improves disease-free survival in intermediate or high-risk prostate cancer patients
- Adding docetaxel to ADT and RT cuts mortality in high-risk prostate cancer with normal testosterone
- Long-term data reveals cribriform-positive status drives metastatic risk in prostate cancer patients
- Extraperitoneal single-port robotic-assisted radical prostatectomy shortens console time by 83 minutes versus multiport transperitoneal approaches in 1997 patients
- Intensity-modulated radiotherapy reduces acute and delayed G2+GI toxicities versus 3D-CRT in high-risk prostate cancer
- AI assistance improves diagnostic accuracy for clinically significant prostate cancer detection via MRI in this systematic review
- Local anaesthetic transperineal biopsy reduces infection and sepsis while improving cancer detection compared to transrectal ultrasonography methods
- 64 Cu-PSMA-617 shows highest detection rates in biochemically recurrent prostate cancer
- PSA-based prostate cancer screening reduces mortality but increases diagnoses
- Polygenic Risk Score Ties to Prostate Cancer Aggressiveness
- NeuroSAFE-guided robot-assisted prostatectomy improves erectile function and continence in men
- Review of bibliometric data shows growing research interest in macrophage polarization strategies for prostate cancer since 2015
- Enzalutamide plus ADT improves 5-year survival in metastatic hormone-sensitive prostate cancer
- Time to biochemical progression predicts second events in high-risk prostate cancer
- PSA levels at 6, 12, and 24 weeks post-randomization correlate with 96-month survival in prostate cancer
- MRgSBRT and replanned CTgSBRT show similar organ-at-risk dosimetry in prostate cancer
- Ultrasound-guided salvage brachytherapy with interstitial hyperthermia shows low toxicity in locally recurrent prostate cancer
- Systematic review and meta-analysis evaluates PRIMARY score on PSMA PET for prostate cancer detection
- PHS601-based stratification increases prostate cancer risk estimates in Norwegian population-based cohorts
- MRI-RSI changes during neoadjuvant ADT and radiotherapy in men with high-risk localized prostate cancer
- Narrative review evaluates urine-based PSMA detection technologies as emerging noninvasive diagnostics for prostate cancer
- Machine learning quantification of Gleason Pattern 4 showed higher discrimination for adverse pathology than grade group in prostate cancer
- Transdermal Estradiol Patches Show Noninferiority to LHRH Agonists in Prostate Cancer Metastasis-Free Survival
- Image-guided radiotherapy dose intensification for intermediate- or high-risk prostate cancer
- Enzalutamide Monotherapy Shows Higher Survival and Metastasis-Free Rates Versus Leuprolide in High-Risk Biochemical Recurrence
- Prolonged nightly fasting plus telehealth coaching showed feasibility in men with prostate cancer on androgen deprivation therapy
- ML-driven decision aid reduces decisional conflict in prostate cancer screening discussions compared to standard education
- Radical perineal prostatectomy shows lower blood loss but similar long-term outcomes to retropubic approach
- Systematic review finds PSA screening reduces prostate cancer mortality but increases overdiagnosis and false positives
- Serum triglyceride levels show no relationship with prostate cancer risk in a meta-analysis of Chinese men
- Liquid biopsy shows high sequencing success in high-risk localized prostate cancer feasibility study
- Systematic review of 2025 RCTs identifies new standards of care across genitourinary cancers
- PET-guided radiation dose escalation linked to improved event-free survival in prostate cancer recurrence
- Targeted plus perilesional biopsy noninferior to combined biopsy for prostate cancer detection
- Prior HoLEP association with longer operative time and catheter duration in subsequent RARP
- Animated video reduces pain and improves satisfaction during transperineal prostate biopsy in RCT
- Lu-PSMA-617 reduces disease progression versus deferred ADT in oligometastatic HSPC in phase 2 trial
- Phase 2 trial of muscadine grape extract added to ADT for recurrent prostate cancer fatigue
- Qualitative study finds knowledge gaps and insurance concerns about prostate cancer genetic testing